anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a food composition keeping excellent flavor of tomato and having excellent blood pressure increase-suppressing activity and useful as a functional food improving essential hypertension, containing serous fluid of a squeezed solution of tomato and/or its condensate as an essential component. SOLUTION: This composition contains serous fluid of a squeezed solution of tomato and/or its condensate as an essential component. The squeezed solution of tomato is usually obtained by crushing raw tomato using a crusher, etc., heating by a tube heater, etc., to perform sterilization and enzyme revitalization, and further squeezing by an extractor, etc. The serous fluid is preferably obtained by subjecting the squeezed solution to a centrifuging at 10,000-15,000G for 8-12hrs and separating a high-molecular weight precipitate. A condensing ratio of the condensate of the serous fluid is, e.g. in a case of using for refreshments, preferably 4-6 times. A water-soluble compound having &lt;=4,000 molecular weight and existing in the serous fluid can be used as an essential component of the objective composition.
PURPOSE:To improve absorption in intestinal tracts and nutrient effects by hydrolyzing an aqueous solution of a protein with an endopeptidase and dipeptidyl carboxypeptidase(DPCP). CONSTITUTION:A culture obtained by culturing Bacillus subtilis HL521, strain, etc., is extracted and purified to afford DPCP having the following properties. Action; liberating peptides in dipeptide units of amino acids from the carboxy terminals of proteins. Optimum pH; 6.0-11.0. Action temperature; about 50 deg.C. Molecular weight; 110000 measured by a gel filtration method, etc. Endopeptidase, a proline-specific endopeptidase, derived from Flavobacterium meningosepticum, etc., and the above-mentioned DPCP are then added to an aqueous solution of soybean protein, etc., to carry out hydrolytic reaction at 25-60 deg.C for 8-72hr and afford a hydrolyzed solution. The resultant hydrolyzed solution ts subsequently purified to produce a low-molecular peptide composition having &lt;=1000 molecular weight.
PROBLEM TO BE SOLVED: To obtaiin a dental calculus suppressing agent containing a water soluble polyphosphoric acid salt and xylitol, and high in dental calculus suppressing effect, and a composition for an oral cavity blended with the same. SOLUTION: This dental calculus suppressing agent is obtained by blending 0.01-10 pts.qt. linear or cyclic water soluble polyphosphoric acid salt of the formula: Mn+2 Pn O3n+1 , and the formula: (MPO3 )n [M is Na or K; (n) is 22; (m) is &gt;=3] with 0.1-80 pts.wt. xylitol. Further, it is preferable to blend 0.001-1 pts.wt. triclosan thereto. By containing the dental calculus suppressing agent, a tooth brushing agent such as a toothpaste, a composition for an oral cavity such as a dental cream or gel, a mouth wash, etc., can be prepared. As the linear polyphosphoric acid salt, sodium triphosphate having (n)=3 and as the cyclic polyphosphoric acid salt, sodium trimetaphosphate having (m)=3, are cited.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new system having no drawbacks of conventional bleaching processes, for dyeing keratin substances, particularly human keratin fibers, particularly hair.  &lt;P&gt;SOLUTION: The invention relates to the dyeing of keratin substances using styryl hydroxy(cyclo)alkylamino thiol/disulfide fluorescent dyes. The invention further relates to a dye composition comprising a styryl hydroxy(cyclo)alkylamino thiol/disulfide fluorescent dye and to a dyeing process with, in particular, a lightening effect on keratin substances such as the hair, using the composition. The invention similarly relates to novel thiol/disulfide fluorescent dyes and to the uses thereof in lightening keratin substances. The composition makes it possible to obtain a lightening effect which is resistant and visible on dark keratin fibers.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Emesis means that because diaphragm and abdominal muscle suddenly contracts, food in stomach is oppressed and expelled from the body through esophagus and mouth cavity. Emesis is divided into central emesis (caused by irritation on vomiting center in nervous system) and reflex emesis (caused by irritation on nerve endings around stomach, intestine and the like). The proved prescription employs Chinese herbal medicines as raw materials, and juice is extracted by employing a conventional medicine decoction method and is taken orally. The proved prescription provided by the invention is none in toxic and side effects and unique in treatment effect. The application scope of the proved prescription comprises: stomach-cold emesis, continuous emesis or yellow water vomit, dysphoria, indigestion emesis, emesis appetite loss and children&#39;s emesis. The proved prescription is subjected to many years of repeated practice, and has a total effective rate of 95% and a curative rate of 92% based on clinical observation on hundreds of patients; the proved prescription has obvious nervous centralis inhibiting effect, is capable of improving human body immunity, is short in treatment course, fast in effectiveness and good in consolidation property, is convenient to take, and is an exclusive integral curative prescription for treating emesis.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain new gene and protein that activate MAP kinase cascade and to provide a method for using them for medicines, diagnostics and medical treatments.  &lt;P&gt;SOLUTION: The new protein phosphorylates Elk1 and/or activates a kinase which phosphorylates Elk1. The DNA encodes the protein. The recombinant vector contains the DNA. The transformant contains the recombinant vector. The method for producing the protein is provided. The antibody against the protein or its partial peptide is obtained. The method for producing the antibody is provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Techniques for implementing a platform configured to interact with a plurality of applications on a computing device to provide health information of an individual. The platform may be implemented by receiving information representative of a health state of an individual. The information may be provided by a sensor associated with the individual and provide data indicating the individual&#39;s physiological and/or emotional state. An indication of the individual&#39;s health state may be generated by selecting a value from a set of values representative of different health states. The indication may be provided through a programming interface to one or more applications. An application may provide context information associated with the individual at a time associated with the individual&#39;s health state, and the context information may be used to generate the indication.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tripeptide which has weak side effects and osteocyte proliferating actions and a method for producing the same.  &lt;P&gt;SOLUTION: The tripeptide having osteocyte proliferating actions is a tripeptide having a structure of Lys-Glu-Ile and osteocyte proliferating actions and all amino acids are L-amino acids and are bonded by a peptide bond. The method for producing the tripeptide comprises a step of adding a protease to an egg membrane obtained from a fish belonging to genus Gadus, Gadidae family, and Clupeidae family and heating the resulting mixture. The amount of the protease added is preferably 0.03-0.5 times the weight of the egg membrane, and the treating temperature is preferably 20-40°C. Furthermore, the obtained tripeptide Lys-Glu-Ile having osteocyte proliferating actions is utilized as an active ingredient of a food preparation, a cosmetic preparation, and a pharmaceutical preparation.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a system and method for providing an access to a clinical data over the Internet.  &lt;P&gt;SOLUTION: This system 10 is provided with a server, and a database 12 connected to the server. The database stores clinical data sets. The system is provided further with a thin client, a communication link between the server and the Internet, and a communication link between the thin client and the Internet. Software running on the server receives a request for one or more clinical data sets, acquires the requested clinical data sets, and transmits the clinical data sets to the thin client.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an epidermal keratinization normalizing agent which activates epidermal keratinizing cells, has an action to promote the expression of involucrin and keratin 10 of the constituting proteins of cornified envelope, and excels in safety.  &lt;P&gt;SOLUTION: The epidermal keratinization normalizing agent comprises an acidic xylooligosaccharide as an active ingredient. The acidic xylooligosaccharide has at least one uronic acid residue in the molecule as a side chain. The uronic acid is glucuronic acid or 4-O-methyl-glucuronic acid. The acidic xylooligosaccharide is obtained by &#34;enzymatically and/or physicochemically treating a lignocellulose material to obtain a complex of a xylooligosaccharide component and a lignin component and then subjecting the complex to acid hydrolysis treatment to obtain a xylooligosaccharide mixture&#34;.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
A process of obtaining a  alpha -lactalbumin enriched product from whey of various origins is disclosed. A first ultrafiltration is carried out on unpasteurized raw whey with membranes having cut-off greater than 5,000 (e.g. 50,000) at a pH between 6.3 and 7 (e.g. 6.6) and a temperature between 30 DEG  and 60 DEG  C. thereby retaining whey proteins. The ultrafiltrate then undergoes a second ultrafiltration with a membrane capable of retaining  alpha -lactalbumin (cut-off about 1,200 and 2,000) which is preferably diafiltration. Depending on whether starting whey is acid whey or sweet whey the resulting product may contain practically no CMP or some (e.g. 25%). The resulting product is useful as a mother&#39;s milk substitute, pharmaceutical, intensive care or therapeutic food, or tryptophan enriched nutrient.
1,197,033. Hair - treating compositions. L&#39;OREAL. 19 April, 1967 [19 April, 1966], No. 18074/67. Heading C3R. [Also in Divisions C4 and D1] A composition used in the treatment of hair comprises at least one alkylated methylol compound having within its formula at least one group in which R is a hydrogen atom, an alkyl radical of 1-4 carbon atoms or an alkoxymethyl radical, R&lt;SP&gt;1&lt;/SP&gt; is an alkyl radical of 1-4 carbon atoms and the nitrogen atom of the group is bonded directly to a group of the formula or to a carbon atom of a triazine ring, and a perfume. The compound may be bis-methoxymethylurea, methoxymethyl urea, ethoxymethylurea, i-propoxymethylurea, trimethoxymethylmelamine, ethyl dimethoxymethyl carbamate, bis - methoxymethyladipamide or bis-butoxymethylurea. The composition may be an aqueous or aqueous-alcoholic solution, the alcohol optionally being the alcohol used to alkoxylate the corresponding methylol compounds, and may contain 0À2-10% by weight of the compound. The composition may have a pH of 1À5-5 and may contain an acid catalyst, e.g. phosphoric, sulphuric, acetic, citric or lactic acid, monosodium or monopotassium phosphate. Dyestuffs, penetrating agents, surface active agents and other additives, e.g. trimethyl cetyl ammonium bromide and a polyvinyl pyrrolidone/vinyl acetate copolymer, may also be added to the composition which may be in the form of a cream, emulsion, gel or aerosol.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a protease inhibitor and antibacterial agent which is effective for the prevention and treatment of periodontal diseases, excellent in safety and used for medical uses and as a foodstuff component.  &lt;P&gt;SOLUTION: The protease inhibitor contains a protein having 5.0 to 6.5 isoelectric point or its partial peptide contained in rice (Oryza sativa) as an active ingredient. The protein or its partial peptide as the active ingredient has a specific amino acid sequence, and inhibitory activity and antibacterial activity against the protease of periodontal disease bacteria, Porphyromonas gingivalis. The oral composition or foodstuff are obtained by adding the above protease inhibitor or antibacterial agent. The nucleic acid has the specific base sequence and encodes the protein having the protease inhibitory activity or antibacterial activity.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To obtain a new compound useful as an external preparation for skin having protecting action on ultraviolet rays free from coloring reaction with a metal ion. CONSTITUTION:A compound of the formula (R&lt;1&gt; is H or methyl; R&lt;2&gt; is 8-18C alkyl or CH2-CH2-CO2R&lt;3&gt;; R&lt;3&gt; is 8-18C alkyl) such as 5-cinnamylidene-3-(2- ethylhexyl)hydantoin. The compound of the formula is obtained by condensing hydantoin with a cinnamaldehyde to give cinnamylidenehydantoin. Then cinnamylidenehydantoin is alkylated or subjected to addition reaction with an acrylic ester to give a compound of the formula. A base for an external preparation for skin is blended with 0.1-20wt.% of the compound of the formula to give an external preparation for skin. The external preparation for skin shows extremely excellent ultraviolet absorbing action on ultraviolet light (UV-A) at long wavelength of 320-400nm.
FIELD: medicine.SUBSTANCE: invention refers to surgical dentistry and maxillofacial surgery. For micropenny sclerotherapy of arteriovenous malformations of the maxillofacial region of the patient, a vascular malignancy of the maxillofacial region of the patient is detected in the position of the patient lying on his back or sitting in an armchair with the help of ultrasonic Dopplerography in the energy mode. Linear sensor is used with frequency of 5–10 MHz in real time. Localization and size of vascular malignancy are evaluated. Skin vascular border marking is applied on the skin. Further, after performing general anesthesia, under the ultrasound control using the linear sensor equipped with the Doppler blood flow analysis option with 5–10 MHz test frequency, the vascularised new growth is punctured by inserting the puncture needle and moving it into the vascular pedicle lumen until the blood drop appears in the puncture needle or in the sterile syringe filled with steroid saline. After that, without changing the position of the needle, a syringe is attached to it with a pre-prepared sclerosing micropenny composition (SMC). When the needle is brought out of the neoplasm of the new growth, the space of the SMC is filled. Herewith, the QMS is prepared before direct introduction into the cavity of the vascular malignancy by mixing the sclerosing preparation with air, carbon dioxide or a mixture of air and carbon dioxide at ratio of 1:3.5 to 1:4.5. Sclerosing agent used is 3 % lauro macrogol 400 or 3 % solution of 2-methyl-7 ethylun-decyl-4 sodium sulphate or 3 % sodium tetradecyl sulphate solution. Herewith, SMK is displaced from vascular neoplasm of blood and inner layer of vein - intima is dissolved. After micropenny scleroobliteration and extraction of puncture needle on maxillofacial area of patient is applied for 3–5 days as a compression bandage sterile plaster &#34;compress&#34; for pressing walls of vein to each other.EFFECT: method provides high clinical effectiveness with obtaining a stable therapeutic effect in the absence of paraesthesia, lymphorrhea and haematomas due to low traumatism of lymphatic pathways and nerve fibers, high cosmetic effect due to absence of scar formation.1 cl, 4 ex
The invention comprises steroids of the formula &lt;FORM:1023798/C2/1&gt; wherein Hal is fluorine, chlorine or bromine, R1 is hydrogen or an aliphatic hydrocarbon group of at most 4 carbon atoms, and R2 is hydrogen or an acyl group of 1 to 18 carbon atoms. They may be prepared by epoxidizing corresponding 4-unsubstituted D 4-steroids and reacting the 4,5-epoxides formed with a hydrogen halide or a hydrogen halide donor; or by directly halogenating the 4-unsubstituted D 4-steroids to give the required products via the not-isolated 4,5-dihalo intermediates; or by halogenating enamines of the D 4 compounds, followed by isomerization of the D 5-4-halogeno compounds. A 17b -hydroxyl group in resulting compounds (including epoxide intermediates) may be esterified.  Examples are given.  The 7a -methyl-androstenes of the invention, which are stated to be anabolics, may be made up into pharmaceutical compositions with suitable carriers.  These may take the form of tablets, dragees, capsules, solutions, suspensions, emulsions, ointments or creams, and may contain preserving, stabilizing, wetting or emulsifying agents, salts for regulating the osmotic pressure, or buffers.
PROBLEM TO BE SOLVED: To provide a method for finely crystallize cisplatin, capable of obtaining fine cisplatin crystals having excellent particle diameters and an excellent particle size distribution in a good yield without using hydrochloric acid and water by mixing the solution of the cisplatin dissolved in a good solvent with an organic solvent which is a poor solvent for the cisplatin but is miscible with the good solvent. SOLUTION: The good solvent for the cisplatin is preferably a solvent having a solubility of &gt;=10 g/L, especially 20-50 g/L, for the cisplatin at 25 deg.C, and is selected from organic amides and the organic sulfoxides. The organic amides include (N-substituted, N,N-disubstituted) formamides, acetamide, propionamide and cyclic amides such as 2-pyrrolidinone. The organic sulfoxides include lower alkyl group-substituted sulfoxides. The poor solvent is a solvent having a solubility of &lt;=5 g/L, preferably 2 g/L, for the cisplatin at 25 deg.C, and is preferably a lower alkanol such as methanol or a halogeno lower alkane such as chloroform. The fine cisplatin crystals suitable as a medicine are thus obtained by the method.
Narcotics and/or anaesthetics for injection into mammals contain a sufficient amt of (a) a steroid of the pregnane gps which displays anaesthetic and/or narcotic effect when injected intravenously (e.g. 3alpha-hydroxy-5beta-pregnant-20-one) (which compounds are potent and rapid acting, and cause little or no irritation of vascular tissue when injected) together with (b) a potentiator such as a 1, 4-benzodiazepine paraldehyde, chloral hydrate or a glycerol phenyl ether of formula (I): (where R1 and R2 are lower alkyl, m and n are 0 or positive integers the sum of which is not &gt;5, and R3 is H or amino), together with (c) an injectable aqs. org. solvent in an amt which is sufficient for an injection prepn. The potentcy of the narcotic/anaesthetic steroid is greatly increased by the potentiator. The pref. potentiators are the 1,4-benzodiazepines.
The invention is named as deodorant of pet&#39;s peculiar smell, which belongs to the field of daily-use chemical technology. Nowadays, more and more people in society raise pets, and raising pet has become a way of depositing people&#39;s affection. However, pets are different from human beings. Even though pets are bathed everyday, still more or less peculiar smell is remained. People mostly use sand, paper, lime and the like in old days, but the effect is limited. The purpose of the invention is to provide a deodorant with convenient use and excellent deodorizing effect. The purpose is realized by churning and mixing a plurality of daily-use chemical materials. The invention can absorb the peculiar smell and bring deodorizing effect, meanwhile the invention has the advantages of safety, innocuity, and convenient use.
1. A method of perfusing a subject, said method comprising: sequentially introducing to said subject a first and second fluid composition, wherein: (a) said first fluid composition is a conventional biological buffer free nonnaturally occurring plasma-like solution comprising: (i) electrolytes; (ii) an oncotic agent;(iii) and a dynamic buffering system; and (b) said second fluid composition is a fluid blood composition. 2. The method according to Claim 1, wherein said electrolytes include: Na&lt;+&gt;, Mg&lt;2+&gt;, Ca&lt;2+&gt;, and Cl&lt;-&gt;. 3. The method according to Claim 2, wherein said non-naturally occurring plasma-like solution further includes K&lt;+&gt;. 4. The method according to Claims 1 to 3, wherein said solution further includes a blood clotting factor. 5. The method according to Claims 1 to 4, wherein said dynamic buffering system comprises an organic carboxylic acid, salt or ester thereof. 6. The method according to Claims 1 to 5, wherein said non-naturally occurring plasma-like solution further includes a sugar selected from the group consisting of monosaccharides and disaccharides. 7. The method according to Claims 1 to 6, wherein fluid blood composition is whole blood or a derivative thereof. 8. The method according to Claim 7, wherein said fluid blood composition is not terminally heat sterilizable. 9. The method according to Claims 1 to 8, wherein said method further comprises the introduction of at least one additional fluid composition. 10. The method according to Claims 1 to 9, wherein said method further comprises reducing the temperature of said subject. 11. The method according to Claims 1 to 10, wherein said method further comprises placing said subject into a hyperbaric environment. 12. A kit for use in a perfusion method, said kit comprising: (a) a conventional biological buffer free synthetic plasma-like solution according to any one of Claims 1 to 8; and (b) instructions for performing the method according to Claim 1. 13. A perfusion system comprising: (a) means for introducing and removing liquid from the circulatory system of a subject; (b) a conventional biological buffer free synthetic plasma-like solution according to any one of Claims 1 to 8; and (c) a fluid blood composition comprising at least one naturally occurring blood component. 14. The system according to Claim 13, wherein said system further comprises a means for modulating the temperature of said subject. 15. The system according to Claim 13 or 14, wherein said system further comprises a means for modulating the pressure of the environment of said subject.
FIELD: medicine, in particular, anesthesiology and reanimatology; applicable in treatment of patients with traumatic shock at early hospital stage. SUBSTANCE: method includes anesthesia, infusion therapy, compensation of blood losses, artificial pulmonary ventilation, medicamentous correction of metabolism disturbances. Intravenous bolus injection of dalargin in a dose of 1 mg is made for stabilization of hemodynamics depending on functional state of blood vascular system with presence of hyperdynamic type of central hemodynamics (cardiac index &gt; 4.2 l (min.sq.m) -1  and peripheral resistance is less than 1200 din.s. -5 ). In case of presence of hypodynamic type of central hemodynamics (cardiac index is less than 2.2 l (min.sq.m) -1  and peripheral resistance is above 2500 din.s.cm -5 ) actovegin in a dose of 2000 mg in 0.9-% solution of sodium chloride of 5-% glucose is injected intravenously at the rate of 20-40 ml/min. EFFECT: higher efficiency. 2 tbl